160 completed, 10 recruiting, 6 active not recruiting, 5 terminated. 61 Phase 1, 48 Phase 2, 39 Phase 3, 16 Phase 4, 1 Not applicable.
Follow Eisai Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of E6742 in Participants With Systemic Lupus Erythematosus E6742, Placebo - Systemic Lupus Erythematosus | Phase 2 | Recruiting | Eisai Co., Ltd. | 256 | 2026-03-31 | 2026-08-21 |
| A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy No Intervention - Biliary Tract Cancer | Recruiting | Eisai Co., Ltd. | 60 | 2025-07-10 | 2026-02-27 | |
| Changes in MTX-PG Concentrations During Subcutaneous MTX Therapy in Patients With Rheumatoid Arthritis(COSMOS Study) Methotrexate (MTX) - Rheumatoid Arthritis (RA) | Phase 4 | Recruiting | Keio University | 100 | 2025-04-10 | 2025-04-06 |
| A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures No Intervention - Partial-Onset Seizures, Primary Generalized Tonic-clonic Seizures | Recruiting | Eisai Co., Ltd. | 110 | 2024-11-18 | 2026-07-01 | |
| A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab No Intervention - Alzheimer's Disease | Recruiting | Eisai Co., Ltd. | 5000 | 2024-02-14 | 2026-01-23 | |
| A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders No Intervention - Psychotic Disorders | Completed | Eisai Co., Ltd. | 579728 | 2023-03-30 | 2023-11-18 | |
| Lemborexant in Delayed Sleep Phase Syndrome Lemborexant, Placebo - Delayed Sleep Phase Syndrome | Phase 4 | Recruiting | University of California, San Francisco | 15 | 2023-03-13 | 2026-06-05 |
| A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder Lemborexant, PBO - Sleep Initiation and Maintenance Disorders | Phase 2 | Completed | Eisai Co., Ltd. | 65 | 2022-11-30 | 2025-07-03 |
| A Single and Multiple Dose Study of Dotinurad in Chinese Healthy Participants Dotinurad - Healthy Volunteers | Phase 1 | Completed | Eisai Co., Ltd. | 26 | 2022-07-01 | 2023-09-14 |
| Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant Laboratory Biomarker Analysis, Lenvatinib - Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Terminated | Emory University | 3 | 2022-04-19 | 2026-04-24 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants E6742, Placebo - Lupus Erythematosus, Systemic | Phase 1 / Phase 2 | Completed | Eisai Co., Ltd. | 26 | 2022-04-14 | 2023-09-29 |
| Lemborexant in Delayed Sleep Phase Syndrome Lemborexant, Placebo - Delayed Sleep Phase Syndrome | Phase 4 | Recruiting | Stanford University | 86 | 2022-02-01 | 2026-10-26 |
| Diagnosis and Monitoring of Disease Progression Using Deep Neuro Signatures Alzheimer's Disease, Mild Cognitive Impairment | Active not recruiting | Altoida | 3500 | 2022-01-31 | 2025-10-03 | |
| Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor Lenvatinib + Letrozole, Fulvestrant - Breast Cancer | Phase 2 | Recruiting | National University Hospital, Singapore | 120 | 2021-12-27 | 2025-07-25 |
| A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout Dotinurad, Febuxostat, Dotinurad Matched Placebo - Gout | Phase 3 | Completed | Eisai Co., Ltd. | 451 | 2021-12-21 | 2025-07-30 |
| A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan Tazemetostat - Lymphoma, Follicular | Active not recruiting | Eisai Co., Ltd. | 145 | 2021-08-16 | 2026-01-02 | |
| A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers Aducanumab - Healthy Volunteers | Phase 1 | Completed | Biogen | 30 | 2021-06-30 | 2023-04-13 |
| NCCH2006/MK010 Trial (FORTUNE Trial) E7090 - Advanced or Recurrent Solid Tumors, FGFR Gene Alterations | Phase 2 | Recruiting | National Cancer Center, Japan | 75 | 2021-06-15 | 2025-10-03 |
| A Study to Assess the Safety and Tolerability of E6742 in Japanese Healthy Adult Participants E6742, Placebo - Healthy Volunteers | Phase 1 | Completed | Eisai Co., Ltd. | 24 | 2020-12-28 | 2021-07-20 |
| A Study of Lemborexant in Chinese Participants With Insomnia Disorder Lemborexant, Placebo - Sleep Initiation and Maintenance Disorders | Phase 3 | Completed | Eisai Co., Ltd. | 194 | 2020-11-06 | 2024-12-20 |
Showing 20 of 185. Sign in to see all of them.
Neoplasms (14) · Arthritis, Rheumatoid (12) · Breast Neoplasms (12) · Seizures (10) · Alzheimer Disease (9) · Epilepsy (9) · Sleep Initiation and Maintenance Disorders (8) · Carcinoma, Hepatocellular (7) · Dementia (7) · Lewy Body Disease (5) · Stomach Ulcer (5) · Acrocephalosyndactylia (4) · Carcinoma (4) · Cognitive Dysfunction (4) · Stomach Neoplasms (4)
lenvatinib (20) · Donepezil (16) · perampanel (14) · Rabeprazole (13) · Adalimumab (12) · eribulin (9) · lemborexant (6) · Eszopiclone (5) · quetmolimab (5) · mecobalamin (4) · eperisone (3) · pembrolizumab (3) · tazemetostat (3) · Diclofenac (2) · E 5555 (2)
Japan (140) · China (17) · South Korea (10) · United States (10) · Taiwan (6) · India (3) · Singapore (3) · United Kingdom (3) · Australia (2) · France (2) · Germany (2) · Greece (2) · Russia (2) · Spain (2) · Argentina (1)
Akira Endo (4) · Hidetaka Hiramatsu (4) · Kai Shibata (3) · Kazunori Saeki (3) · Nobuyuki Sugisaki (3) · Soo Chin Lee (3) · Andrew D Krystal, MD, MS (2) · Atsushi Kamijo (2) · Chifumi Kitamura (2) · Hiroki Shimizu (2) · Hiroshi Obaishi (2) · Katsuya Sugizaki (2) · Kazuhiro Omata (2) · Kazuko Kobayashi (2)
PMID 35305920, PMID 22325170, PMID 25982504, PMID 37059702, PMID 20881072, PMID 21376385, PMID 21887501, PMID 22108775, PMID 22149875, PMID 22731653, PMID 23053683, PMID 23063301, PMID 23860537, PMID 23957383, PMID 24441150, PMID 24874893, PMID 25024001, PMID 25242374, PMID 25245624, PMID 25380636, PMID 25502863, PMID 25605862, PMID 25713599, PMID 25713600, PMID 27338778, PMID 27704266, PMID 27919207, PMID 28299283, PMID 28502925, PMID 28660549, PMID 28670237, PMID 28681650, PMID 29188387, PMID 29250772, PMID 29352704, PMID 29363235, PMID 30054164, PMID 30509941, PMID 30578206, PMID 30623276, PMID 30636701, PMID 30638399, PMID 30928806, PMID 31365116, PMID 32381018, PMID 32589866, PMID 32716739, PMID 33038062, PMID 33198671, PMID 33474967
2015 (1), 2016 (1), 2018 (1), P30CA138292 (1)